China Resources Pharmaceutical Group Ltd
HKEX:3320
Net Margin
China Resources Pharmaceutical Group Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
HK |
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
32.6B HKD |
1%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
734.9B USD |
23%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
366.6B USD |
24%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
208.1B CHF |
14%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
188.4B CHF |
24%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
158.5B GBP |
14%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
199B USD |
27%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
137.5B USD |
13%
|
China Resources Pharmaceutical Group Ltd
Glance View
In the vast and dynamic landscape of China's healthcare sector, China Resources Pharmaceutical Group Ltd. has emerged as a formidable player. Born from the rich heritage of its parent conglomerate, China Resources Holdings, the company weaves together a complex tapestry of pharmaceutical manufacturing, distribution, and retail operations. Its diversified operations ensure that it maintains a robust footprint across the entire pharmaceutical value chain. The company's manufacturing arm is a powerhouse, producing a vast array of products, including traditional Chinese medicine and modern pharmaceuticals, catering to the diverse needs of health consumers in China and beyond. Leveraging its extensive industry expertise and a deep understanding of the local market, China Resources Pharmaceutical crafts products that blend innovation with time-honored traditions, effectively meeting the growing demands for quality healthcare solutions. On the distribution and retail front, China Resources Pharmaceutical Group employs its extensive and well-integrated network to efficiently channel its products across the nation. The strategic positioning of its distribution centers enables it to serve hundreds of thousands of pharmacies, hospitals, and healthcare institutions, ensuring broad accessibility. Retail operations round out the company's comprehensive approach, with a wide-reaching chain of drugstores under its banner offering not only medicinal products but also healthcare services. This holistic business model not only diversifies revenue streams but also strengthens the company's ability to weather industry shifts, making it a resilient entity in the ever-evolving pharmaceutical and healthcare milieu. Through its multifaceted approach, China Resources Pharmaceutical Group Ltd. continues to play a crucial role in shaping the future of healthcare in China, navigating challenges and opportunities with the acuity expected of an industry leader.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on China Resources Pharmaceutical Group Ltd's most recent financial statements, the company has Net Margin of 1.3%.